WebFeb 17, 2024 · Our Pipeline at a glance. We have a proud legacy of turning breakthrough science into medicines and vaccines that save and improve lives around the world. We are focused on discovering new solutions for today and the future. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible. WebMay 13, 2024 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative …
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery …
WebDec 19, 2016 · KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, has been approved in Japan for the … WebApr 29, 2024 · ODAC Voted in Favor of Maintaining US Indications for KEYTRUDA® (pembrolizumab) in Certain Patients With Advanced Urothelial Carcinoma (Bladder Cancer) and Hepatocellular Carcinoma (Liver Cancer); ODAC Voted Against Maintaining US Indication for KEYTRUDA in Certain Patients With Gastric Cancer KENILWORTH, N.J., … cta red purple bypass
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New …
WebFeb 17, 2024 · The chart reflects the company research pipeline as of February 17, 2024. Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 … WebMar 28, 2024 · The collaboration will allow for the evaluation of safety and efficacy of BJ-001, a tumor-targeting IL-15 fusion protein, in combination with MSD's anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in ... WebKEYTRUDA ist als Monotherapie zur adjuvanten Behandlung des Nierenzellkarzinoms mit erhöhtem Rezidivrisiko nach Nephrektomie oder nach Nephrektomie und Resektion … cta refers to